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Background: It is uncertain whether gender differences in outcome after primary percutaneous coronary
intervention (PCI) are only attributable to different baseline characteristics or additional factors.
Methods: Databases of two German myocardial infarction network registries were combined with a total of 1104
consecutive patients admitted with acute ST-elevation myocardial infarction (STEMI) and treated according to
standardized protocols.
Results: Approximately 25% of patients were females. Mean age (69 vs 61 years), incidence of diabetes (28% vs
20%), hypertension (68 vs 58%) and renal insufficiency (26% vs 19%) was significantly higher compared to males.
Mean prehospital delay was numerically longer in females (227 vs 209 min) as was in hospital delay (35 vs 30 min).
PCI was finally performed in 92% of females and 95% of males with comparable procedural success (95% vs 97%).
Use of drug eluting stents (55% vs 68%) and application of GP 2b 3a blockers (75% vs 89%) was significantly less
frequent in women. At discharge, prescription of beta blockers and lipid lowering drugs was also significantly lower
in females (84% vs 90% and 71% vs 84%). Unadjusted in-hospital mortality was significantly higher in females
(10% vs 5%) without attenuation after 12 months. Adjusted mortality however did not differ significantly between
genders.
Conclusion: Higher unadjusted mortality in females after primary PCI was accompanied by significant differences in
baseline characteristics, interventional approach and secondary prophylaxis in spite of the same standard of care.
Lower guideline adherence seems to be less gender specific but rather a manifestation of the risk-treatment paradox.
Keywords: Primary PCI, Myocardial infarction network, Gender differencesBackground
Gender differences in outcome after acute ST-elevation
myocardial infarction (STEMI) are well known [1-5].
This holds true irrespective of performance of mechan-
ical reperfusion with primary percutaneous coronary
intervention (PCI) in most large observations [6,7], al-
though there are single contradictory reports [8]. There
is some uncertainty whether higher mortality in females
is only attributable to different baseline characteristics or* Correspondence: rbirkemeyer@t-online.de
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article, unless otherwise stated.additional factors such as delayed diagnosis and reperfu-
sion, under-treatment or genuine gender specific differ-
ences in therapeutic susceptibility [1-9]. Female STEMI
patients usually present at higher mean age than males
and therefore at higher risk. Interactions between higher
risk and less intensive treatment, the risk-treatment para-
dox, have been described [10-12].
Our objective was to compare indicators of guideline
adherent therapy in a large cohort of consecutive
STEMI patients according to gender in the defined set-
ting of a myocardial infarction network aiming at pri-
mary PCI for all STEMI patients according to the same
treatment algorithm. For this purpose we combined
data from two German myocardial infarction networktral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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works had shown that more than 90% of the regional
STEMI population received primary PCI after network
implementation. In the cohort of patients who did not
receive any revascularization attempt, mainly because of
age and comorbidities, the proportion of females was
reduced from 77% to 44% [13].
Methods
Network structures
Both networks aim at reperfusion therapy with primary
PCI for all regional STEMI patients according to a uni-
form, regional treatment protocol during 24h/7d a week
in one interventional centre.
Network A is located in the North-eastern Germany
and comprises both an urban and a rural catchment area
with a population of approximately 415.000 inhabitants.
The diameter of the network area is up to 120 km. At
the time of data collection there were eight hospitals in
the network area, seven of them without cathlabs and
one with a high-volume interventional facility and a
24h/7d primary PCI service. Emergency medical services
(EMS) transferred STEMI patients to the nearest hos-
pital without announcement. After admission local
emergency departments alarmed the interventional team
and organized direct transfer to the cathlab.
Network B is located in the South-western Germany
and comprises a rural catchment area with a population of
approximately 350.000 inhabitants. The diameter of the
network area is up to 70 km. At the time of data collection
there were six hospitals in the network area, five of them
without cathlabs and one with a high-volume interven-
tional facility and a 24h/7d primary PCI service. Network
structures included 12-lead ECG in the ambulance, ECG
telemetry to the intensive care unit of the invasive facility,
a structured phone call between EMS and the intensive
care physician on call and preparation of the cathlab be-
fore patient arrival. STEMI patients were intended to be
directly admitted to the cathlab, irrespective of the pres-
ence of cardiogenic shock or resuscitation.
Primary PCI protocol
All patients were treated with 250–500 mg aspirin intra-
venously and received a weight adjusted unfractionated
heparin dose of 70 IU/kg by EMS or the emergency de-
partment. A clopidogrel loading dose of 600 mg was ad-
ministered either by EMS or the emergency department
in most cases. Otherwise, it was given directly before or
immediately after the intervention. Operators of patients
in shock were encouraged to treat all presumably
hemodynamically relevant non-target lesions. Thromb-
ectomy, periprocedural GP2b3a blockers (predominantly
abciximab) and drug eluting stents were used at the dis-
cretion of the operator. Full dose anticoagulation withheparin was stopped after PCI, unless there was a high
thromboembolic risk (e.g. atrial fibrillation or mechan-
ical heart valves).Study population
Consecutive STEMI patients admitted for primary PCI
were prospectively included in their respective registries,
in network A from 2001 to 2003 (n = 603) and in net-
work B from 2005 to 2007 (n = 501).Definitions
The diagnosis of ST-elevation acute myocardial infarction
was based on the presence of chest pain lasting > 20 min
and of significant ST-segment elevation (>0.1 mV in two
adjacent leads if leads I-III, aVF, aVL, V4-V6, and ≥ 0.2 mV
in leads V1-V3), as recorded in the first ECG obtained.
Patients with persistent angina and presumably new left
bundle branch block were included in the registry if
myocardial infarction was subsequently confirmed. Cardio-
genic shock was defined clinically by the presence of
hypotension (systolic blood pressure < 90 mm Hg for ≥30
minutes or need for vasopressors to maintain systolic blood
pressure >90 mm Hg) and tachycardia (heart rate >90
beats/min) with evidence of end-organ hypo-perfusion [14].
Thrombolysis In Myocardial Infarction (TIMI) flow grades
were assessed in the culprit vessel before and after the PCI
procedure. No reflow was defined as TIMI 0 flow after suc-
cessful interventional treatment of the culprit lesion.
Major bleeding was defined according to the TIMI
major bleeding definition as intracerebral bleeding, bleed-
ing requiring surgical intervention, bleeding requiring
transfusion or loss of more than 5 g% haemoglobin [15].
As indicators of guideline adherent therapy we ana-
lysed pre- and in-hospital delays, procedural success of
primary PCI, stent use, peri-interventional antiplatelet
management, medication at discharge and medication at
12 months [16]. Procedural success was defined as re-
sidual stenosis < 30% of the culprit lesion.
For outcomes we analysed mortality, re-infarction rate,
TLR and TVR until 12 month.Data collection and follow-up
All patients were prospectively documented in a dedi-
cated database. Follow-up was obtained from telephone
interviews and questionnaires at 6 and 12 months.
Complete follow-up concerning mortality was obtained
from state registries.
The registry was approved by the Freiburg Ethics
Commission International. All patients were asked for
their written informed consent for the extension of our
routine follow-up.
Table 1 Baseline clinical characteristics according to gender
Women (n = 281) Men (n = 823) p value
Age (yrs.) 69 ± 11 61 ± 12 < 0.01
Diabetes 28% 20% < 0.01
Current smoker 23% 46% < 0.01
Arterial hypertension 68% 58% < 0.01
Hyperlipidemia 41% 46% 0.21
Creatinine clearance < 60 ml/min 26% 19% < 0.01
Previous myocardial infarction 7% 11% 0.12
Previous PCI 5% 8% 0.06
Peripheral artery disease 3% 5% 0.31
Previous TIA/stroke 7% 4% 0.09
Cardiogenic shock 10% 10% 0.96
Post CPR 6% 9% 0.15
Systolic blood presssure 134 ± 3 131 ± 1 0.14
Diastolic blood pressure 74 ± 2 75 ± 1 0.77
Heart rate 81 ± 2 76 ± 1 <0.01
Data presented as mean value ± SD or percentage of patients.
CPR: cardiopulmonary resuscitation, PCI: percutaneous coronary intervention.
Table 2 Reperfusion delays and primary PCI details according to gender
Women (n = 281) Men (n = 823) p value
Pre-hospital delay (min)* 169 (104;296) 158 (90;278) 0.08
In-hospital delay (min)* 18 (7;39) 15 (6,31) 0.07
Announced EMS escorted transfer 55% 56% 0,75
No coronary artery stenosis > 50% 1% 2% 0.97
Multivessel disease 48% 48% 0.97
Culprit vessel LAD 41% 43% 0.70
Culprit vessel LMS 1% 0% 0,70
PCI performed 92% 95% 0.07
Multivessel PCI performed 5% 4% 0,80
Further staged PCI 19% 21% 0,51
Staged CABG 1% 3% 0,12
Average number of stents implanted§ 1.41 1.45 0,69
Stent length (mm)§ 29.2 30.9 0.36
Minimal stent diameter (mm)§ 2.9 3.2 0.15
Drug eluting stent 55% 68% 0,03
Peri- or intraprocedural GP2b3a blocker 75% 89% <0.01
Residual diameter stenosis after PCI < 30% 95% 97% 0.12
Pre-procedural TIMI 0/3 flow§ 60%/17% 60%/17% 0.99
Post-procedural TIMI 0/3 flow§ 6%/81% 7%/82% 0,23
*Data analysed in the 216 females and 708 males where symptom onset could be clearly assigned to the 12h period before hospital admission; pre-hospital delay:
symptom onset until admission to interventional hospital; in-hopital delay: admission until start of angiography.
§Complete data only available from network B.
Data presented as median with interquartile ranges or percentage of patients.
CABG; coronary artery bypass grafting; EMS: emergency medical services; LAD: left anterior descendant; LMS: left main stem; PCI: percutaneous coronary
intervention.
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Table 3 In-hospital bleeding complications according to
gender
Women (n = 281) Men (n = 823) P value
Major bleeding* 6% 2% < 0.01.
Minor bleeding§ 4% 7% 0.22
Insignificant bleeding$ 19% 14% 0.21
Data presented as percentage of patients.
*intra-cerebral bleeding, bleeding requiring surgical intervention or transfusion,
loss of haemoglobin≥ 5g%; §haematuria, haematemesis, loss of haemoglobin ≥
3g% and <5 g% with or≥ 4g% and < 5g% without identifiable source of bleeding;
$bleedings not fulfilling the criteria of a major or minor bleeding.
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Data was analyzed according to established standards of
descriptive statistics. Categorical variables were com-
pared by χ2 test. Continuous variables are reported as
mean ± standard deviation or median with interquartile
ranges. For comparisons, the t test or the two-tailed
Mann–Whitney U test was used as appropriate. Odds
ratios and 95% confidence intervals were provided where
appropriate. A p value of less than 0.05 was considered
significant.
A multivariate logistic regression analysis (stepwise
forward model) with gender as a fixed parameter was
performed to determine independent factors predicting
12-month mortality. The following 6 variables were identi-
fied: age, beta-blocker medication at discharge, diabetes,
lipid lowering medication at discharge, shock and renal
impairment. The logistic model showed a good predictive
value (C-statistic = 0.85), and good calibration characteris-
tics using the Hosmer-Lemeshow test (p = 0.78).
Mortality at 12 months was adjusted for covariates
and for propensity score alone, as well as for the cova-
riates with propensity score added as an additional
covariate.
Results
One thousand one hundred and four consecutive pa-
tients (n = 1104) with the diagnosis of acute STEMI wereTable 4 Medication at discharge and 12 months according to
At discharge
Women Men




Triple therapy 8% 8%
Beta-Blocker 84% 90%
ACE inhibitor 76% 79%
Lipid lowering drug 71% 84%
Data presented as percentage of patients.
*12-month data only available for network B.prospectively included in the combined registries: 281
women and 823 men.
Mean age (69 vs 61 years, p < 0.01), incidence of dia-
betes (28% vs 20%, p < 0.01), hypertension (68% vs 58%,
p < 0.01) and renal insufficiency (26% vs 19%, p < 0.01)
was significantly higher in females compared to males.
However, significantly more males were smokers (23% vs
46%, p < 0.01). 9% of patients in both groups were in car-
diogenic shock. 6% of females and 9% of males were ad-
mitted after resuscitation (p = 0.2) (Table 1).
Mean transfer distances were nearly identical in both
groups (21 km). EMS escorted 55% and 56% of female
and male patients as announced STEMI to the primary
PCI centre. Mean pre-hospital delay was insignificantly
longer in females (227 vs 209 min, p = 0.2) as was in-
hospital delay (35 vs 30 min, p = 0.4). PCI was finally per-
formed in 92% of females and 95% of males (p = 0.1) with
comparable procedural success (95% vs 97%, p = 0.1). Use
of drug eluting stents (55% vs 68%, p = 0.03) and applica-
tion of GP2b3a blockers (75% vs 89%, p < 0.01) was signifi-
cantly less frequent in women (Table 2).
In spite of lesser use of GP2b3a blockers major bleed-
ing was encountered significantly more often in females
(6% vs 2%; p < 0.01) (Table 3).
At discharge prescription of beta-blockers and lipid low-
ering drugs was also significantly lower in females (84% vs
90%, p < 0.01 rsp. 71% vs 84%; p < 0.01). These differences
were more pronounced in network A. Numerical differ-
ences in prescription persisted at 12 months (data only
available for network B) (Table 4).
Unadjusted in-hospital mortality was significantly higher
in females (10% vs 5%, p < 0.01). Difference persisted dur-
ing the first year without attenuation (15% vs 7%, p < 0.01).
Re-infarction, target lesion revascularisation and target
vessel revascularisation rates were numerically lower in fe-
males within the first year after the index event (Table 5).
However, after adjustment by propensity score or co-
variates, female gender failed to be predictive as explana-





value(n = 97) (n = 375)
0.05 56% 65% 0.07
0.02 31% 40% 0.10
0.80 8% 5% 0.20.
0.69 0% 2% 0.20.
<0.01 51% 61% 0.06
0.18 50% 58% 0.15
<0.01 53% 61% 0.14
Table 5 Major adverse cardiac events until 12 months
according to gender
Women Men p value
Mortality:
In-hospital 10.0% 4.5% < 0.01
6-month 14.2% 6.9% < 0.01
12-month 14.9% 6.9% <0-01
STEMI* 1.9% 3.8% 0.31
NSTEMI* 1.9% 2.0% 0.90
Clinically driven TLR* 3,7% 6.6% 0.28
Clinically driven TVR* 5.6% 7.4% 0.54
Definite stent thrombosis*§ 0.9% 2.3% 0.46
Data presented as percentage of patients.
NSTEMI: non ST-elevation myocardial infarction; STEMI: ST-elevation myocardial
infarction; TLR: target lesion revascularisation; TVR: target
vessel revascularisation.
*Complete data only available from network B.
§ARC definition.
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The analysis of 1104 consecutive STEMI patients admit-
ted for primary PCI according to the uniform standard of
care of a myocardial infarction network, showed that early
and late mortality in females was more than double the
mortality of males. This was accompanied by significant
differences in baseline characteristics as has been de-
scribed in a number of previous observations [1-5]. Mean
age of women presenting with STEMI was approximately
eight years older compared to men. Furthermore inci-
dence of diabetes, hypertension and renal impairment was
significantly higher in the female cohort.
Comparable gender differences in mortality have been
found in large registries [1-5]. Single observations re-
ported, however, similar unadjusted mortality of males
and females after primary PCI [8]. This might be due to
different patient selection.Explanatory variable female gender :
Adjusted by propensity score
Adjusted by covariates









Figure 1 Death at 12 months. Explanatory variable female gender: unadj
propensity score as additional covariate (details under “Statistical methods”Under network conditions more than 90% of all regional
STEMI patients are treated with primary PCI rendering
the analysis highly representative for an unselected STEMI
population suitable for revascularisation. We have shown
that in the remaining subset of predominantly elderly pa-
tients who are not scheduled for any revascularisation at-
tempt females were not overrepresented [13].
A unisex standard of care for STEMI patients reflects
current guidelines [16,17] with primary PCI being the
preferred reperfusion strategy for both genders. It has
been demonstrated that primary PCI is equally effective
in men and women [18,19].
Although standard of care in the network regions was
not gender specific, actual treatment showed relevant
differences. There was a trend to more frequent abortion
of intended PCI in females, although the proportion of
patients without significant coronary artery disease and
patients with multi-vessel disease was quite comparable
in both cohorts. In contrast to our finding, a significantly
higher proportion of non-obstructive coronary artery
disease has been previously described in female com-
pared to male ACS patients in a large meta-analysis [1];
this difference was however smallest in the subset of
ACS patients presenting with STEMI. The use of drug
eluting stents and GP2b3a blockers was significantly
lower in females whereas pre- and in-hospital delays be-
fore primary PCI were only numerically longer and the
immediate result of primary PCI comparable. Reduction
of system related time delays before primary PCI is obvi-
ously a primary objective of myocardial infarction net-
works and has been successfully proven [13,20-23].
Attempts to intervene on patient related time delays
showed no similar success [24]. A comparable pattern of
slightly increased system delays and lesser use of drug
eluting stents and GP blockers seen in females has also
been shown in elderly network patients [25].OR 95% CI P-value








usted, adjusted by propensity score, covariates or by covariates with
).
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tion of beta-blockers and lipid lowering drugs as well as
the numerically lower prescription of anti-platelets in fe-
males at discharge. The differences in anti-platelet medi-
cation cannot be fully explained by the slight differences in
the need for anticoagulation, but rather by the significantly
higher incidence of major bleedings in females during hos-
pitalisation in spite of less aggressive peri-interventional
platelet management. Higher bleeding rates after primary
percutaneous intervention in females have been described
in many observations [26-28]. The lesser prescription of
betablockers in females cannot explained by lower blood
pressure or heart rate on admission. Numerical differences
in recommended secondary prophylaxis persisted over 12
months. Thus adherence to guideline recommended ther-
apy was lower in females than males. Again, this pattern of
less guideline adherent secondary prophylaxis in females
has also been observed in elderly patients [25].
Multivariate analysis suggested that both the different
baseline characteristics as well as the lesser use of rec-
ommended secondary prophylaxis had an independent
influence on mortality. Interestingly, female gender
failed to be predictive as explanatory variable for mortal-
ity after adjustment by propensity score or covariates. So
there was no implication of gender differences in suscepti-
bility to primary PCI or of a gender specific general under
use of therapy in this analysis. The observed differences in
guideline adherence with respect to secondary prophylaxis
might be more related to the different baseline character-
istics which clearly attributed a higher risk to females.
The risk-treatment paradox has been previously de-
scribed [10-12]. Actually, myocardial infarction networks
counteract this paradox by aiming at higher reperfusion
rates also in high risk patients (especially the elderly and
shock patients) [13,20-23]. This raises the question if the
reluctant use of recommended secondary pharmaco-
logical prophylaxis in the subset of high risk elderly
women reflects a residual under use of justified therapy
or a truly higher prevalence of contra-indications to this
therapy. At least with respect to antiplatelet therapy, in-
creased bleeding risk seemed to be a limiting factor.
Our data also confirmed the previous description of a
lower target lesion and target vessel revascularisation
rate during long term follow up in females compared to
males [29]. It is however questionable if this is primarily
attributable to gender specific biological reactions as this
phenomenon was also described for the comparison of
octogenarians with younger patients after stenting in an
all-comer population [30].
Limitations
A major limitation is the lack of external monitoring of
the registries which is an inherent weakness of many
investigator-driven observational studies.A further limitation of our registry is that we only in-
cluded primary PCI patients and not all regional STEMI
patients. Therefore our analysis cannot be extended to
the complete STEMI population. Preceding analyses,
however, showed that in the setting of a myocardial in-
farction network more than 90% of the STEMI popula-
tion were scheduled for mechanical reperfusion.
Conclusions
Higher unadjusted mortality in females after primary PCI
was accompanied by significant differences in baseline
characteristics, interventional approach and secondary
prophylaxis in spite of a gender neutral standard of care
which enabled similar reperfusion rates and attenuation of
time delays before primary PCI. Lower guideline-adherence
in females in this setting seemed to reflect predominantly a
residual risk-treatment paradox and not a gender specific
under-treatment. Adjusted mortality showed a favourable
trend for females.
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